Denmark Ceases Administering J&J/Janssen COVID-19 Vaccine due to Side Effect Concerns

Denmark’s health authority announced they would be dropping the J&J/Janssen COVID-19 vaccine from its rollout due to its potential link to a rare but serious form of a blood clot.

The Danish Health Authority said it “has concluded that the benefits of using the COVID-19 vaccine from Johnson & Johnson do not outweigh the risk of causing the possible adverse effect, VITT, in those who receive the vaccine. Therefore, the Danish Health Authority will continue the Danish mass vaccination program against COVID-19 without the COVID-19 vaccine from Johnson & Johnson.”

Denmark, which has also stopped administering the AstraZeneca vaccine said it would rely only on the Pfizer/BioNTech and Moderna vaccines in the meantime. 

Stopping the Johnson and Johnson vaccine rollout will also affect the vaccination rollout for Danish citizens aged between 20 and 39 by up to four weeks.

Denmark has only vaccinated 11.5 percent of its population and has gradually eased back it to normalcy since March. 

There have been no Johnson & Johnson shots that have been administered in Denmark so far.

The US has already temporarily stopped administering the Johnson and Johnson shot last month after 17  incidents of severe blood clotting were reported. 

© Fourth Estate® — All Rights Reserved.
This material may not be published, broadcast, rewritten or redistributed.